Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX009 in Lupus Nephritis
NCT05780515Phase 1Completed
- Sponsor
- Annexon Biosciences
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ANX009 in lupus nephritis (LN), sponsored by Annexon Biosciences. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events. Started Aug 2022; status: completed.
02
Drugs
ANX009
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05780515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780515.